- Home
- PVLA vs AQST Comparison
PVLA vs AQST Comparison
Compare PVLA & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PVLA
- AQST
- Stock Information
- Founded
- PVLA 2015
- AQST 2004
- Country
- PVLA United States
- AQST United States
- Employees
- PVLA N/A
- AQST N/A
- Industry
- PVLA Biotechnology: Pharmaceutical Preparations
- AQST Biotechnology: Pharmaceutical Preparations
- Sector
- PVLA Health Care
- AQST Health Care
- Exchange
- PVLA Nasdaq
- AQST Nasdaq
- Market Cap
- PVLA 249.2M
- AQST 272.9M
- IPO Year
- PVLA N/A
- AQST 2018
- Fundamental
- Price
- PVLA $25.92
- AQST $4.07
- Analyst Decision
- PVLA Strong Buy
- AQST Strong Buy
- Analyst Count
- PVLA 7
- AQST 7
- Target Price
- PVLA $46.29
- AQST $11.29
- AVG Volume (30 Days)
- PVLA 129.2K
- AQST 1.3M
- Earning Date
- PVLA 08-15-2025
- AQST 08-05-2025
- Dividend Yield
- PVLA N/A
- AQST N/A
- EPS Growth
- PVLA N/A
- AQST N/A
- EPS
- PVLA N/A
- AQST N/A
- Revenue
- PVLA N/A
- AQST $54,228,000.00
- Revenue This Year
- PVLA N/A
- AQST N/A
- Revenue Next Year
- PVLA N/A
- AQST $45.71
- P/E Ratio
- PVLA N/A
- AQST N/A
- Revenue Growth
- PVLA N/A
- AQST 5.29
- 52 Week Low
- PVLA $11.17
- AQST $2.12
- 52 Week High
- PVLA $29.27
- AQST $5.80
- Technical
- Relative Strength Index (RSI)
- PVLA N/A
- AQST 72.86
- Support Level
- PVLA N/A
- AQST $3.62
- Resistance Level
- PVLA N/A
- AQST $3.80
- Average True Range (ATR)
- PVLA 0.00
- AQST 0.19
- MACD
- PVLA 0.00
- AQST 0.05
- Stochastic Oscillator
- PVLA 0.00
- AQST 95.43
About PVLA Palvella Therapeutics Inc. Common Stock
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.